Assistant Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Robert L. Schlossman, MD
|
|
Give Review
Robert Schlossman is an expert in the field of Oncology. He went to Tufts University School of Medicine. Tufts University School of Medicine is ranked 49 in research and 52 in primary care medicine He over the years received 1 awards: "Super Doctor". Robert Schlossman is a published doctor and has 31 publications published. The lastest was: 'Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: ...' He is registered with Medicare.
Publications
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple Myeloma: ...
- Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy.
- Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple Myeloma.
- Outcomes in patients with relapsed or refractory multiple Myeloma in a phase I study of everolimus in combination with lenalidomide.
- A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory Myeloma.
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory Myeloma.
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple Myeloma who have received lenalidomide and bortezomib.
- Endothelial stress products and Coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.
- The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms(*).
- Management of relapsed and relapsed/refractory multiple Myeloma.
- MGUS and smoldering myeloma: the most prevalent of plasma Cell dyscrasias.
- Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple Myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
- A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple Myeloma.
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple Myeloma.
- Tumor Cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
- Tailoring treatment for multiple myeloma patients with relapsed and refractory Disease.
- Complications of multiple Myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
- Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple Myeloma.
- Novel therapies in the treatment of multiple Myeloma.
- Single-agent bortezomib in previously untreated multiple Myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neu...
- Clinical, radiographic, and biochemical characterization of multiple Myeloma patients with osteonecrosis of the jaw.
- High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A Systematic review and meta-analysis of randomized ...
- A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple Myeloma.
- GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma Cells in the bone marrow microenvironment.
- Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma Cells.
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple Myeloma.
- 2-Methoxyestradiol overcomes drug resistance in multiple myeloma Cells.
- The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma Cells in the bone marrow mi...
- Arsenic trioxide inhibits growth of human multiple myeloma Cells in the bone marrow microenvironment.
- Comparable outcome with T-Cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.
Schools
Tufts University School Of Medicine
Mt Sinai Hospital
Dana Farber Carncer Institute
Georgetown University Hospital
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
Brigham and Women's Hospital -
Georgetown University Hospital -
Mount Sinai School of Medicine -
Tufts University School of Medicine
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1326001215 | |
| NPPES Provider LastName | SCHLOSSMAN | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 022155418 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 473.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 38.0 | |
| Percent Opioid Claims | 8.03 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1326001215 |
| Last Name Of The Provider | SCHLOSSMAN |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. Robert H. Gottlieb, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce E. Johnson, MD |
|
|
Dr. Glenn Dranoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James A. Decaprio, MD |
|
|
Dr. Jack S. Leitner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George D. Demetri, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. William C. Hahn, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Vincent T. Ho, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Timothy J. Ernst, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John G. Krikorian, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Charles Rosenbaum, MD
This Doctor is OpenDoctor Recommended.
|